Please login to the form below

Not currently logged in
Email:
Password:

Merck to launch Tredaptive internationally

Merck is to commence the launch of its cholesterol drug, Tredaptive in international markets by Q3 2009

Merck is to commence the launch of its cholesterol drug, Tredaptive in international markets by Q3 2009.

Tredaptive (also known as Cordaptive) is a therapy for patients with mixed dyslipidemia and primary hypercholesterolemia. It has been licensed in the EU for use in combination with statins or as a monotherapy when statins are inappropriate.

It is approved for use in 39 countries outside of the US. The FDA refused to approve the drug for use in the US until more supporting evidence was available.

"Merck is pleased that we are now able to supply Tredaptive in approved markets and continue our long-standing commitment to help address unmet medical needs in cardiovascular care," said Dr Luciano Rossetti, senior vice president and franchise head, atherosclerosis and cardiovascular, Merck Research Laboratories.

19th May 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

Unlocking the potential of science and technology in the UK
Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...

Infographics